Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The HER-2/ neu oncogene is a member of the erb B-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/ neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/ neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CNVs are involved in a large number of complex human diseases such as Down’s syndrome (trisomy 21) and many cancers, for example HER2 gene amplification in breast cancer (BC) (1–5).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [5]
In the citing paper
“In a seminal study, Slamon et al. found that HER2 is amplified in about 20% of breast cancers (Slamon et al., 1987).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Slamon et al., 1987
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
Greenberg, M. E., & Ziff, E. B. (1984) · Nature · doi:10.1038/311433a0 · Cited by 3,064
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationClose similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citation
Research works printed but not linked: 1
- Maniatis, T., Molecular Cloning: A Laboratory Manual: 282 (1982).
Cited by
Items 301–400 of 1,056
Wang, Z. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 430
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Tumor progression and metastasis
Yokota, J. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.497 · Cited by 426
Baselga, J., Carbonell, X., Castañeda-Soto, N.-J., Clemens, M., Green, M., Harvey, V., Morales, S., Barton, C., & Ghahramani, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.014 · Cited by 425
Recent trends in epidemiology of brain metastases: an overview.
Tabouret, É., Chinot, O. L., Métellus, P., Tallet, A. R., Viens, P., & Gonçalvès, A. (2012) · PubMed · Cited by 423
Perez, E. A., Barrios, C., Eiermann, W., Toi, M., Im, Y.-H., Conte, P., Martin, M., Pienkowski, T., Pivot, X., Burris, H. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4887 · Cited by 420
Brain Metastases: The HER2 Paradigm
Lin, N. U., & Winer, E. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2478 · Cited by 417
Role of Curcumin in Cancer Therapy
Shishodia, S., Chaturvedi, M. M., & Aggarwal, B. B. (2007) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2007.04.001 · Cited by 413
Lenferink, A. E. G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3385 · Cited by 413
“Overexpression of the wild-type human protein leads to phenotypic transformation of cultured cells (Di Fiore et al., 1987; Hudziak et al., 1987), and is frequently observed in several types of human carcinomas (Slamon et al., 1987, 1989).”
BackgroundVitamin A and retinoid signaling: genomic and nongenomic effects
Al Tanoury, Z., Piskunov, A., & Rochette-Egly, C. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r030833 · Cited by 408
Pituskin, E., Mackey, J. R., Koshman, S., Jassal, D., Pitz, M., Haykowsky, M. J., Pagano, J. J., Chow, K., Thompson, R. B., Vos, L. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.7830 · Cited by 408
“of the ErbB protein family, is overexpressed in approximately 20% to 25% of patients with breast cancer and is associated with early disease progression.(1) Addition of trastuzumab to adjuvant regimens for treatment of HER2-positive early breast cancer (EBC) has significantly improved”
BackgroundCarlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2702 · Cited by 407
Weber, R. G., Boström, J., Wolter, M., Baudis, M., Collins, V. P., Reifenberger, G., & Lichter, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14719 · Cited by 407
Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406
Self-citationFehrenbacher, L., Cecchini, R. S., Geyer Jr, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., Crown, J. P., Polikoff, J., Boileau, J.-F., Provencher, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01455 · Cited by 404
Venter, D., Kumar, S., Tuzi, N., & Gullick, W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92736-x · Cited by 404
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Autocrine, paracrine and juxtacrine signaling by EGFR ligands
Singh, A. B., & Harris, R. C. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.026 · Cited by 400
Nicolson, G. L. (1988) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(88)90010-8 · Cited by 399
Armstrong, S. A., Kung, A. L., Mabon, M. E., Silverman, L. B., Stam, R. W., Den Boer, M. L., Pieters, R., Kersey, J. H., Sallan, S. E., Fletcher, J. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00003-5 · Cited by 398
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer
Signoretti, S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1918 · Cited by 397
Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., Hinrichs, M. J. M., Bezabeh, B. Z., Fleming, R. L., Dimasi, N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.008 · Cited by 397
“C sion of HER2 often leads to constitutive receptor activation and therefore aggressive tumor growth (Slamon et al., 1987).”
BackgroundZuo, T., Wang, L., Morrison, C., Chang, X., Zhang, H., Li, W., Liu, Y., Wang, Y., Liu, X., Chan, M. W. Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.034 · Cited by 395
“A well-established mechanism responsible for HER-2 overexpression in human cancer is gene amplification (Slamon et al., 1987).”
InfluentialBiobanking in health care: evolution and future directions
Coppola, L., Cianflone, A., Grimaldi, A. M., Incoronato, M., Bevilacqua, P., Messina, F., Baselice, S., Soricelli, A., Mirabelli, P., & Salvatore, M. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1922-3 · Cited by 394
Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene
Bouchard, L., Lamarre, L., Tremblay, P. J., & Jolicoeur, P. (1989) · Cell · doi:10.1016/0092-8674(89)90331-0 · Cited by 393
Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.9694 · Cited by 392
Chen, W. W., Schoeberl, B., Jasper, P. J., Niepel, M., Nielsen, U. B., Lauffenburger, D. A., & Sorger, P. K. (2009) · Molecular Systems Biology · doi:10.1038/msb.2008.74 · Cited by 391
“Hyperactive and aberrant ErbB signaling has been implicated in a wide variety of human cancers and is a frequent target of pharmaceutical intervention (Slamon, 1987; Rusch, 1993; Engelman, 2007).”
BackgroundPress, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J.-Y., & Bernstein, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.094 · Cited by 391
Self-citationN-Glycans in cancer progression
Lau, K. S., & Dennis, J. W. (2008) · Glycobiology · doi:10.1093/glycob/cwn071 · Cited by 390
“For example, expression of epidermal growth factor receptor (EGFR) family members in breast cancer correlates with aggressive tumor behavior and reduced survival time (Slamon et al. 1987).”
BackgroundLocoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype
Lowery, A. J., Kell, M. R., Glynn, R. W., Kerin, M. J., & Sweeney, K. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1891-6 · Cited by 389
“The importance of HER2/neu receptor status as a driver of prognosis is well recognized [45] and targeted therapy has been developed in the form of trastuzumab.”
BackgroundErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Hattingen, E., Harter, P. N., Mittelbronn, M., Tonn, T., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 388
Robidoux, A., Tang, G., Rastogi, P., Geyer, C. E., Azar, C. A., Atkins, J. N., Fehrenbacher, L., Bear, H. D., Baez-Diaz, L., Sarwar, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70411-x · Cited by 386
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
Clayton, A. J., Danson, S., Jolly, S., Ryder, W. D. J., Burt, P. A., Stewart, A. L., Wilkinson, P. M., Welch, R. S., Magee, B., Wilson, G., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601970 · Cited by 385
“Amplification of the HER-2 gene with overexpression of the receptor is detected in 20–30% of breast cancers (Slamon et al, 1987, 1989) and is associated with a worse prognosis compared to those with HER-2-negative tumours (Slamon et al, 1987; Emi et al, 2002).”
BackgroundTrastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0106 · Cited by 385
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080161 · Cited by 384
“Overexpression and/or gene amplification of HER2 was found in various types of human cancer and especially in human breast carcinomas where HER2 gene amplification has been identified with a frequency of 30% (Slamon et al. 1987, 1989).”
BackgroundSelf-citationCyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half, E., Tang, X., Gwyn, K. M., Şahin, A. A., Wathen, K., & Sinicrope, F. A. (2002) · PubMed · Cited by 384
Xu, J., Chen, Y., & Olopade, O. I. (2010) · Genes & Cancer · doi:10.1177/1947601910378691 · Cited by 382
Viani, G. A., Afonso, S. L., Stefano, E. J., De Fendi, L. I., & Soares, F. V. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-153 · Cited by 381
“, Basel, Switzerland), a monoclonal antibody directed against HER-2, improves survival and quality of life when given in combination with taxanes as first-line therapy in women with metastatic breast cancer [3-5] and has shown efficacy as monotherapy [6,7].”
BackgroundCauwe, B., Van den Steen, P. E., & Opdenakker, G. (2007) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230701340019 · Cited by 381
“It is overexpressed in 25% to 30% of breast cancers, and it has been associated with high risks of relapse and death (Slamon et al., 1987), although the prognostic value of HER2 has been the matter of some controversy (Ross et al., 2003).”
BackgroundTan, P., Cady, B., Wanner, M., Worland, P. J., Cukor, B., Magi‐Galluzzi, C., Lavin, P. T., Draetta, G. F., Pagano, M., & Loda, M. F. (1997) · PubMed · Cited by 380
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Chen, M. H., Kerkelä, R., & Force, T. (2008) · Circulation · doi:10.1161/circulationaha.108.776831 · Cited by 379
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
MEDINA, P., & GOODIN, S. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.008 · Cited by 377
Hussain, M. H. A., MacVicar, G. R., Petrylak, D. P., Dunn, R. L., Vaishampayan, U., Lara, P. N., Chatta, G. S., Nanus, D. M., Glode, L. M., Trump, D. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0994 · Cited by 376
Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., Miyazaki, I., Endou, Y., Tanaka, M., & Sasaki, T. (1991) · PubMed · Cited by 375
Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374
Targeted proteomic strategy for clinical biomarker discovery
Schiess, R., Wollscheid, B., & Aebersold, R. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2008.12.001 · Cited by 373
“Later, it was found to be amplified in up to 30% of invasive breast cancers and its over-expression to be associated with a poor prognosis (Slamon et al., 1987).”
Backgroundp27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2
Chu, I., Sun, J., Arnaout, A., Kahn, H., Hanna, W., Narod, S., Sun, P., Tan, C.-K., Hengst, L., & Slingerland, J. (2007) · Cell · doi:10.1016/j.cell.2006.11.049 · Cited by 372
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 371
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway
Zhou, B. P., Hu, M. C.-T., Miller, S. A., Yu, Z., Xia, W., Lin, S.-Y., & Hung, M.-C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8027 · Cited by 371
Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 370
Cappuzzo, F., Varella-Garcia, M., Shigematsu, H., Domenichini, I., Bartolini, S., Ceresoli, G. L., Rossi, E., Ludovini, V., Gregorc, V., Toschi, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.111 · Cited by 369
The type 1 (EGFR-related) family of growth factor receptors and their ligands
Prigent, S. A., & Lemoine, N. R. (1992) · Progress in Growth Factor Research · doi:10.1016/0955-2235(92)90002-y · Cited by 369
Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue
Stingl, J., Eaves, C. J., Zandieh, I., & Emerman, J. T. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010615124301 · Cited by 367
“ErbB-2 is also overexpressed in 25–30% of human mammary tumors where it is associated with a poor prognosis [13, 14].”
BackgroundIs overexpression of HER-2 a predictor of prognosis in colorectal cancer?
Kavanagh, D. O., Chambers, G., O' Grady, L., Barry, K. M., Waldron, R. P., Bennani, F., Eustace, P. W., & Tobbia, I. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-1 · Cited by 367
“Slamon et al demonstrated that this is over expressed in 30% of patients with breast cancer [4].”
BackgroundThe multiethnic cohort study: exploring genes, lifestyle and cancer risk
Kolonel, L. N., Altshuler, D., & Henderson, B. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1389 · Cited by 367
STAT3 as a central mediator of neoplastic cellular transformation
Frank, D. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.10.017 · Cited by 364
The erbB3 gene product is a receptor for heregulin.
Carraway, K. L., Sliwkowski, M. X., Akita, R., Platko, J. V., Guy, P. M., Nuijens, A., Diamonti, A. J., Vandlen, R. L., Cantley, L. C., & Cerione, R. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36789-3 · Cited by 362
Ono, M., & Kuwano, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0646 · Cited by 362
Guarneri, V., Lenihan, D. J., Valero, V., Durand, J.-B., Broglio, K., Hess, K. R., Michaud, L. B., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Esteva, F. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9551 · Cited by 361
Lineage dependency and lineage-survival oncogenes in human cancer
Garraway, L. A., & Sellers, W. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1947 · Cited by 360
Mass, R. D., Press, M. F., Anderson, S., Cobleigh, M. A., Vogel, C. L., Dybdal, N., Leiberman, G., & Slamon, D. J. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.026 · Cited by 359
Self-citationTrastuzumab‐associated cardiotoxicity
Keefe, D. L. (2002) · Cancer · doi:10.1002/cncr.10854 · Cited by 358
Signaling Pathways in Cancer and Embryonic Stem Cells
Dreesen, O., & Brivanlou, A. H. (2007) · Stem Cell Reviews · doi:10.1007/s12015-007-0004-8 · Cited by 357
Janjigian, Y. Y., Werner, D., Pauligk, C., Steinmetz, K., Kelsen, D. P., Jäger, E., Altmannsberger, H. M., Robinson, E., Tafe, L. J., Tang, L. H., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds104 · Cited by 356
“E-cadherin mutations in gastric carcinoma [1] (multiple letters).”
BackgroundJänicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Höfler, H., & Graeff, H. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf01833260 · Cited by 355
“Some of the recently evaluated prognostic indicators are used to analyze prognosis within defined subgroups of patients [23, 45 ].”
MethodBradley, R., Braybrooke, J., Gray, R., Hills, R., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00288-6 · Cited by 354
Self-citationYu, D., Jing, T., Liu, B., Yao, J., Tan, M., McDonnell, T. J., & Hung, M.-C. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80157-4 · Cited by 353
CD44 variant exon epitopes in primary breast cancer and length of survival
Kaufmann, M., von Minckwitz, G., Heider, K.-H., Ponta, H., Herrlich, P., & Sinn, H.-P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90521-9 · Cited by 353
Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., & Slamon, D. J. (1999) · PubMed · Cited by 353
Self-citationBoku, N. (2014) · Gastric Cancer · doi:10.1007/s10120-013-0252-z · Cited by 351
“cancer, resulting in HER2-positive subtypes, is associated with very poor prognosis compared with HER2-negative breast cancer [1, 18].”
BackgroundAmiri-Kordestani, L., Blumenthal, G. M., Xu, Q. C., Zhang, L., Tang, S. W., Ha, L., Weinberg, W. C., Chi, B., Candau-Chacon, R., Hughes, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0012 · Cited by 351
Müller, P., Kreuzaler, M., Khan, T., Thommen, D. S., Martin, K., Glatz, K., Savic, S., Harbeck, N., Nitz, U., Gluz, O., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4925 · Cited by 349
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Meric-Bernstam, F., Johnson, A. M., Dumbrava, E. E. I., Raghav, K., Balaji, K., Bhatt, M., Murthy, R. K., Rodon, J., & Piha-Paul, S. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2275 · Cited by 349
Gene Copy-Number Alterations: A Cost-Benefit Analysis
Tang, Y.-C., & Amon, A. (2013) · Cell · doi:10.1016/j.cell.2012.11.043 · Cited by 348
“ERBB2, which encodes the EGFR receptor HER2, is amplified in ~30% of primary breast cancers (Slamon et al., 1987).”
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Pernas, S., & Tolaney, S. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833519 · Cited by 348
Ottenhoff-Kalff, A. E., Rijksen, G., van Beurden, E. A., Hennipman, A., Michels, A. A., & Staal, G. E. J. (1992) · PubMed · Cited by 348
Lichter, A. S., Lippman, M. E., Danforth, D. N., d'Angelo, T., Steinberg, S. M., deMoss, E., MacDonald, H. D., Reichert, C. M., Merino, M., & Swain, S. M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.976 · Cited by 347
Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K., Siegel, P. M., Hung, M.-C., Yarden, Y., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.672-683.2000 · Cited by 347
“In primary human breast tumors, a splice variant of ErbB-2 encoding a similar ECD deletion which can also transform Rat-1 fibroblasts has been detected, suggesting that such activating mutants of ErbB-2 may similarly have a critical role in human breast cancer induction and progression (62).”
BackgroundResultInfluentialKallioniemi, O., Holli, K., Visakorpi, T., Koivula, T., Helin, H. H., & Isola, J. J. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490504 · Cited by 346
Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., & Cheever, M. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3363 · Cited by 345
Moody, S. E., Sarkisian, C. J., Hahn, K. T., Gunther, E. J., Pickup, S., Dugan, K. D., Innocent, N., Cardiff, R. D., Schnall, M. D., & Chodosh, L. A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00212-x · Cited by 345
Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344
Cyclin E, a Potential Prognostic Marker in Breast Cancer.
Keyomarsi, K. (1997) · doi:10.21236/ada341275 · Cited by 344
“DNA and by overproduction of its mRNA and protein (3).”
BackgroundTsuda, H., Hirohashi, S., Shimosato, Y., Hirota, T., Tsugane, S., Yamamoto, H., Miyajima, N., Toyoshima, K., Yamamoto, T. S., & Yokota, J. (1989) · PubMed · Cited by 341
Pellikainen, J. M., Ropponen, K. M., Kataja, V. V., Kellokoski, J. K., Eskelinen, M. J., & Kosma, V.-M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1061 · Cited by 339
Gomez, H. L., Doval, D. C., Chavez, M. A., Ang, P. C.-S., Aziz, Z., Nag, S., Ng, C., Franco, S. X., Chow, L. W. C., Arbushites, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0590 · Cited by 338
Epidemiology of Triple-Negative Breast Cancer: A Review
Howard, F. M., & Olopade, O. I. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000500 · Cited by 338
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
“Approximately 20% of breast cancers exhibit HER2 gene amplification/overexpression, resulting in an aggressive tumor phenotype and reduced survival (3, 4).”
BackgroundFan, R., Kim, N.-G., & Gumbiner, B. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216462110 · Cited by 336
Tumor targeting using anti-her2 immunoliposomes
Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D., & Benz, C. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00315-7 · Cited by 335
Ariazi, E. A., Clark, G. M., & Mertz, J. E. (2002) · PubMed · Cited by 335
Self-citationTrastuzumab: triumphs and tribulations
Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 334
“Overexpression of HER2, with subsequent constitutive kinase activation, is found in approximately 20–30p of human breast cancers, primarily owing to gene amplification, and is associated with reduced disease-free and overall survival (”
BackgroundDevelopment and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Dijkers, E. C. F., Kosterink, J. G. W., Rademaker, A. P., Perk, L. R., van Dongen, G. A. M. S., Bart, J., de Jong, J. R., de Vries, E. G. E., & Lub-de Hooge, M. N. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060392 · Cited by 334
“HER2/ neu overexpression or amplification occurs in a wide range of human cancers, including breast (incidence, 20%230%), colon, lung, and ovarian cancers (2,3).”
BackgroundThe Hsp90 chaperone complex as a novel target for cancer therapy
Goetz, M. P., Toft, D. O., Ames, M. M., & Erlichman, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg316 · Cited by 334
“Her-2 (p185) is a receptor tyrosine kinase overexpressed in a significant proportion of malignancies, including breast, ovarian, prostate and gastric cancers, and is associated with a poor prognosis [32, 33].”
BackgroundWeigelt, B., Lo, A. T., Park, C. C., Gray, J. W., & Bissell, M. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0502-2 · Cited by 334
“The human epidermal growth factor receptor type 2 (HER2) is amplified and overexpressed in about 15–20% of all breast cancers and associated with aggressive disease and poor prognosis [18].”
BackgroundPredictive biomarkers: a paradigm shift towards personalized cancer medicine
La Thangue, N. B., & Kerr, D. J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.121 · Cited by 332
Allelic Loss in Colorectal Carcinoma
Kern, S. E. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03420210047014 · Cited by 331
Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis
von Deimling, A., von Ammon, K., Schoenfeld, D., Wiestler, O. D., Seizinger, B. R., & Louis, D. N. (1993) · Brain Pathology · doi:10.1111/j.1750-3639.1993.tb00721.x · Cited by 331
Mittendorf, E. A., Wu, Y., Scaltriti, M., Meric-Bernstam, F., Hunt, K. K., Dawood, S., Esteva, F. J., Buzdar, A. U., Chen, H., Eksambi, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1735 · Cited by 330
Metadata
- Authors
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L.
- Affiliations
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Genentech (US)
- Venue
- Science
- Published
- 1987-01-09
- Volume
- 235
- Issue
- 4785
- Pages
- 177-182
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141393790
- Cited by
- 11,760
- References
- 44
- Citations by year
- 2026: 209 · 2025: 230 · 2024: 301 · 2023: 309 · 2022: 302 · 2021: 346 · 2020: 336 · 2019: 325 · 2018: 344 · 2017: 395 · 2016: 416 · 2015: 433 · 2014: 486 · 2013: 549 · 2012: 459
- FWCI
- 103.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA36827, CA-30195)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- gene amplification, breast cancer, prognostic factors, relapse, overall survival, lymph node-positive disease, hormone receptor status, ErbB family, epidermal growth factor receptor
- MeSH terms
- Axilla, Breast Neoplasms, DNA, Female, Gene Amplification, Humans, Lymph Nodes, Neoplasm Recurrence, Local, Nucleic Acid Hybridization, Oncogenes, Prognosis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.